2359695-48-8
Chemical Structure
Deferoxamine-DBCO
Synonym(s): DFO-DBCO
- CAS No.: 2359695-48-8
- Formula:C44H61N7O10
- Molecular Weight:848.00
InChIKey: LFESCIZZXSUBAV-UHFFFAOYSA-N
SMILES: CC(N(CCCCCNC(CCC(N(CCCCCNC(CCC(N(CCCCCNC(CCC(N1CC2=C(C=CC=C2)C#CC3=C1C=CC=C3)=O)=O)O)=O)=O)O)=O)=O)O)=O
Biological Activity: Deferoxamine-DBCO (DFO-DBCO) is a bifunctional small-molecule synthetic building block obtained by covalent conjugation of the DFO metal-chelating group with DBCO, and is a bifunctional chelator. Deferoxamine-DBCO efficiently chelates radioactive metals (such as 89Zr) through the DFO moiety to achieve radiolabeling. Deferoxamine-DBCO undergoes a metal-free Huisgen cycloaddition reaction with azide-containing biomolecules (such as siRNA and monoclonal antibodies) through the DBCO moiety under bioorthogonal conditions to accomplish targeted conjugation. Deferoxamine-DBCO is applicable to research related to bioconjugation chemistry and the preparation of PET radiotracer probes[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Deferoxamine-DBCO | 89.08% | Deferoxamine-DBCO (DFO-DBCO) is a bifunctional small-molecule synthetic building block obtained by covalent conjugation of the DFO metal-chelating group with DBCO, and is a bifunctional chelator. Deferoxamine-DBCO efficiently chelates radioactive metals (such as 89Zr) through the DFO moiety to achieve radiolabeling. Deferoxamine-DBCO undergoes a metal-free Huisgen cycloaddition reaction with azide-containing biomolecules (such as siRNA and monoclonal antibodies) through the DBCO moiety under bioorthogonal conditions to accomplish targeted conjugation. Deferoxamine-DBCO is applicable to research related to bioconjugation chemistry and the preparation of PET radiotracer probes. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Pringle TA, et al. Synthesis and Evaluation of a Site-specifically Labeled Radioimmunoconjugate for Dual-Modal (PET/NIRF) Imaging of MT1-MMP in Sarcomas. Bioconjugate chemistry. 2022 Aug 17;33(8):1564-1573.
- [2]. Madajewski B, et al. Molecular Engineering of Ultrasmall Silica Nanoparticle-Drug Conjugates as Lung Cancer Therapeutics. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020 Oct 15;26(20):5424-5437.
